The only platform that connects VA claims from initial decision to final judgment — and shows what actually wins. Search 1,850,000+ BVA decisions, CAVC appeals, 38 CFR regulations, and M21-1 policy with AI-powered analysis.
Paste any BVA decision and get a per-issue breakdown, evidence gap analysis, and a draftable argument outline — grounded in 1.85M+ real cases and government sources.
All data comes directly from official government sources: BVA decisions from va.gov, CAVC docket from the Court's eFiling system, CFR from the Electronic Code of Federal Regulations, and M21 policy from the VA's KnowVA system.
Both. Veterans can understand their own claims. VSOs, accredited agents, and attorneys get deeper research tools including advanced search, AI-powered case analysis, docket tracking, and alerts.
This authoritative guide outlines the legal framework for COVID-19 VA claims, focusing on Public Law 116-315 presumptions and the strategic use of analogous ratings for Long COVID. It provides attorneys and veterans with the evidentiary requirements necessary to establish service connection and maximize disability compensation through the BVA.
Winning a COVID-19 related claim at the Board of Veterans' Appeals (BVA) requires a sophisticated understanding of the intersection between the temporary presumptive period established by Public Law 116-315 and the traditional requirements for direct and secondary service connection under 38 CFR § 3.303 and § 3.310. The most successful strategies do not merely claim 'COVID-19' as a disability, but rather identify and document the specific chronic sequelae—often referred to as 'Long COVID' or Post-Acute Sequelae of SARS-CoV-2 (PASC). Because the VA does not have a dedicated diagnostic code for COVID-19, the BVA relies heavily on 38 CFR § 4.20, which allows for analogous ratings. Practitioners must focus on the 'functional loss' of the affected body systems, such as the respiratory, neurological, or cardiovascular systems, to secure a rating that reflects the veteran's actual level of impairment. Evidence must go beyond a simple positive test result. The BVA looks for 'continuity of symptomatology' as defined in 38 CFR § 3.303(b). This means providing a longitudinal medical record that tracks symptoms from the acute phase of the infection through the development of chronic conditions like interstitial lung disease, chronic fatigue syndrome, or postural orthostatic tachycardia syndrome (POTS). A high-quality Medical Nexus Opinion (IMO) is critical, particularly one that utilizes the 'at least as likely as not' standard and cites peer-reviewed medical literature linking the initial viral insult to the current chronic disability. For claims involving the presumptive period (March 1, 2020, to January 5, 2024), the strategy should emphasize that the veteran met the 48-hour active duty requirement and manifested symptoms to a degree of 10% or more within the qualifying window, even if a formal diagnosis was delayed due to the pandemic's impact on healthcare access.
The strategic approach to a COVID-19 VA claim must be bifurcated: first, establishing service connection, and second, securing an appropriate rating through analogous coding. For the initial filing (VA Form 21-526EZ), do not simply list 'COVID-19.' Instead, list the specific residuals, such as 'Chronic Respiratory Failure secondary to COVID-19' or 'Cognitive Impairment (Brain Fog) secondary to COVID-19.' This forces the C&P examiner to evaluate the specific body systems affected. If the veteran served on active duty for at least 48 hours during the period of March 1, 2020, to January 5, 2024, the claim should explicitly invoke Public Law 116-315, Section 2007. This law creates a presumption that the infection occurred in service if symptoms manifested to a 10% degree of disability during that window. During the evidence development phase, the focus must be on 'functional loss' as defined in 38 CFR § 4.40 and § 4.45. Since there is no COVID-19 diagnostic code, the BVA will look to 38 CFR § 4.20 to find a comparable condition. For example, if the veteran has lung scarring, the claim should be analogized to Diagnostic Code 6825 (Diffuse Interstitial Fibrosis). If the primary symptom is profound fatigue, consider DC 6354 (Chronic Fatigue Syndrome). The goal is to provide the BVA with a 'roadmap' for rating. When facing a C&P exam, the veteran must be prepared to describe their 'worst day.' Because COVID residuals are often episodic or fluctuate in severity, the veteran must emphasize the limitations they experience during flare-ups. If the C&P examiner provides an unfavorable opinion, the strategy should shift to a Supplemental Claim or a BVA appeal. At the BVA level, the focus should be on the 'Benefit of the Doubt' rule (38 CFR § 3.102). If the medical evidence is in 'approximate equipoise'—meaning the veteran's private nexus is as persuasive as the VA's negative opinion—the BVA is legally mandated to rule in favor of the veteran. Attorneys should draft a 'Brief in Support of the Appeal' that highlights the specific clinical findings and lay testimony that the lower-level adjudicators ignored, specifically pointing to the 'continuity of symptomatology' and the systemic nature of the viral damage.